Dr. Schreiber brings expertise the field of tumor immunology and is co-inventor of significant elements of Heat's ImPACT Technology platform. He has more than 10 years of lab experience and skills in the discovery of therapeutic immuno-oncology compounds. Dr. Schreiber is also a co-inventor of TNFRSF25 agonist technology and has authored numerous tumor immunology and heat shock protein-based cancer immunotherapy abstracts and publications.
Jeff Wolf, chief executive officer of Heat, said, "Dr. Schreiber has been intimately involved in the progression of gp96 heat shock protein immunotherapy both as a Ph.D. researcher and as a post-doctoral fellow in the laboratory of Eckhard Podack, M.D., Ph.D., the inventor of Heat's ImPACT Technology platform. Under Taylor's leadership, the Company will seek to generate and evaluate its proprietary ImPACT Therapy for new potential immunotherapeutic oncology product opportunities including the potential for use in combination with checkpoint inhibitors and T-cell costimulatory compounds."